World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
192731
World Ranking
2630
National Ranking
272

Rury R. Holman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rury R. Holman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 697 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Rury R. Holman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rury R. Holman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Rury R. Holman is affiliated with the University of Oxford in the United Kingdom. Their research primarily lies within the field of Medicine, with a significant focus on Endocrinology, Diabetes and Metabolism, as well as Cardiology and Cardiovascular Medicine. Holman's work also spans Surgery, Molecular Biology, and Physiology.

The scientist's research topics cover various aspects of diabetes treatment and management, alongside cardiovascular function and associated risk factors. The main topics of their work include:

  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Cardiovascular Function and Risk Factors
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Pancreatic function and diabetes
  • Diet and metabolism studies
  • Heart Rate Variability and Autonomic Control

Holman has contributed to several recent papers, reflecting collaborations with researchers in cardiovascular medicine and diabetes. Notable publications include:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021, The Lancet)
  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021, The Lancet)
  • Empagliflozin in acute myocardial infarction: the EMMY trial (2022, European Heart Journal)
  • Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88 (2021, Diabetes Care)
  • Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II) (2020, Cardiovascular Diabetology)

Frequent coauthors in Holman's work include Ruth L. Coleman, Robert J. Mentz, Naveed Sattar, John B. Buse, and Adrian F. Hernandez, with collaboration counts ranging from 22 to 33 publications each. This indicates ongoing partnerships in research activities related to their fields of study.

The scientist has published extensively in several academic journals, with the highest number of publications appearing in:

  • Circulation (12 publications)
  • Diabetes Care (11 publications)
  • UNC Libraries (9 publications)
  • Diabetes Obesity and Metabolism (9 publications)
  • Cardiovascular Diabetology (7 publications)

Best Publications

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

    R C Turner;R R Holman;C A Cull;I M Stratton

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

    R Turner;C Fox;Matthews;H McElroy

  • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

    Irene M Stratton;Amanda I Adler;H Andrew W Neil;David R Matthews

  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

    R C Turner;R R Holman;I M Stratton;C A Cull

  • 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

    Rury R. Holman;Sanjoy K. Paul;M. Angelyn Bethel;David R. Matthews

  • Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

    Scott M. Grundy;H. Bryan Brewer;James I. Cleeman;Sidney C. Smith

  • Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

    David M. Nathan;John B. Buse;Mayer B. Davidson;Ele Ferrannini

  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

    UK Prospective Diabetes;RR Holman;SE Manley;R Turner

  • International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial.

    Andrew Molyneux;Richard Kerr;Irene Stratton

  • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

    Kahn Se;Haffner Sm;Heise Ma;Herman Wh

  • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

    R C Turner;C A Cull;V Frighi;R R Holman

  • International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes

    David M. Nathan;Beverly Balkau;Enzo Bonora;Knut Borch-Johnsen

  • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

    R Turner;R Holman

  • Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

    A. I. Adler;I. M. Stratton;H. A. W. Neil;J. S. Yudkin

  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

    Jennifer B Green;M. Angelyn Bethel;Paul W Armstrong;John B Buse

  • Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

    R C Turner;H Millns;H A W Neil;I M Stratton

  • U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease

    R C Turner;C A Cull;I M Stratton;S E Manley

  • Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

    Amanda I. Adler;Richard J. Stevens;Sue E. Manley;Rudy W. Bilous

  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

    rosiglitazone Medication Trial Investigators;H C Gerstein;S Yusuf

  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

    Rury R. Holman;M. Angelyn Bethel;Robert J. Mentz;Vivian P. Thompson

Frequent Co-Authors

John B. Buse
John B. Buse University of North Carolina at Chapel Hill
John J.V. McMurray
John J.V. McMurray University of Glasgow
Alastair Gray
Alastair Gray University of Oxford
Eric D. Peterson
Eric D. Peterson The University of Texas Southwestern Medical Center
Steven M. Haffner
Steven M. Haffner The University of Texas Health Science Center at San Antonio
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Jaakko Tuomilehto
Jaakko Tuomilehto University of Helsinki
Adrian F. Hernandez
Adrian F. Hernandez Duke University
Andrew T. Hattersley
Andrew T. Hattersley University of Exeter
Ewan R. Pearson
Ewan R. Pearson University of Dundee

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If traditional medical school isn't the right fit, or you’re seeking flexible education options, a variety of online degrees can open doors to rewarding healthcare careers. Many accredited universities now offer degree programs that blend online coursework with clinical experience, making it easier to advance in the medical field while managing work or family commitments.

Aspiring nurse leaders can consider the best DNP programs online, providing advanced practice knowledge and leadership skills. For those interested in medications and patient care, an online pharmacy degree is a flexible option that prepares students for pharmacist licensure.

For a technology-focused route, an online health information management degree can help launch or advance a career managing medical records and health data. Alternatively, if you’re looking for a shorter pathway into healthcare, consider the average cost of medical billing and coding program to enter the vital field of healthcare administration.

These online pathways offer diverse opportunities for those passionate about healthcare, even without a traditional MD path.

Best Scientists Citing Rury R. Holman

Trending Scientists

Recently Published Articles